Table 2.

Clinical characteristics of 13 mantle cell lymphoma patients who received allogeneic stem cell transplant.

UPN	Sex	Age	Morphology	Stage	BM involvement	MIPI	Relapse after ASCT		Salvage therapy bridging to allo-SCT	State before allo-SCT	Survival at last follow up	Overall survival*
1	Male	44	Classic	IV	Yes	Low	Yes	4 cycles of bortezomib + rituximab + bendamustine		CR	Alive in remission	88
8	Male	61	Classic	IV	Yes	Low	Yes	3 cycles of bortezomib + rituximab + bendamustine		CRu	Death due to infection	26
13	Male	52	Blastoid	IV	Yes	Low	Nil	ibrutinib		PR	Alive in remission	28
14	Male	49	Classic	III	Nil	High	Nil	1 cycle of asparaginase + paclitaxel + gemcitabine		PR	Alive in remission	140
34	Male	48	Classic	IV	Yes	Low	Yes	8 cycles of bortezomib + rituximab + bendamustine		CRu	Alive in remission	82
36	Female	66	Blastoid	IV	Yes	High	Yes	Nil		Refractory	Death due to infection	18
41	Female	52	Blastoid	IV	Yes	Low	Yes	Venetoclax		PR	Alive in remission	25
46	Male	63	Classic	IV	Yes	High	Nil	3 cycles of Ibrutinib + rituximab + bendamustine		CR	Alive in remission	11
47	Female	36	Classic	IV	Yes	intermediate	Yes	2 cycles of R-BOMES		CR	Death due to MCL	68
52	Male	52	Classic	IV	Yes	Low	Nil	Not reported		PR	Alive in remission	61
82	Male	42	Classic	III	Nil	intermediate	Yes	1 cycle of bortezomib + mitoxantrone + dexamethasone		PR	Death due to infection	132
85	Male	47	Classic	IV	Yes	Low	Nil	Not reported		PR	Death due to MCL	61
89	Male	50	Classic	IV	Yes	High	Yes	2 cycles of rituximab + bendamustine		CR	Alive in remission	24

CR complete remission, Cru complete remission, unconfirmed, MIPI mantle cell lymphoma international prognostic index, PR partial remission, PD progression of disease, R-BOMES Rituximab, carmustine (BCNU), Vincristine, Methotrexate Etoposide, Methylprednisolone, UPN unlinked patient number.

*Months.